57 related articles for article (PubMed ID: 19732574)
1. Pramlintide in pediatric type 1 diabetes.
Fennoy I
J Pediatr; 2009 Sep; 155(3):308-9. PubMed ID: 19732574
[No Abstract] [Full Text] [Related]
2. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
Chase HP; Lutz K; Pencek R; Zhang B; Porter L
J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
[TBL] [Abstract][Full Text] [Related]
3. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
4. Diabetes drug update: how 4 new options stack up.
Taylor JR; Campbell KM
J Fam Pract; 2007 Mar; 56(3):207-15. PubMed ID: 17343811
[No Abstract] [Full Text] [Related]
5. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
6. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
7. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
8. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
[TBL] [Abstract][Full Text] [Related]
9. Symlin up close. How people are benefiting from this injected drug.
Spake A
Diabetes Forecast; 2008 Mar; 61(3):50-1. PubMed ID: 18446978
[No Abstract] [Full Text] [Related]
10. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.
Thompson RG; Pearson L; Kolterman OG
Diabetologia; 1997 Nov; 40(11):1278-85. PubMed ID: 9389419
[TBL] [Abstract][Full Text] [Related]
11. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
[TBL] [Abstract][Full Text] [Related]
12. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
[TBL] [Abstract][Full Text] [Related]
13. Insulin's sidekicks. Developing alternative medications for type 1 diabetes.
Berg EG
Diabetes Forecast; 2013 Sep; 66(9):38-40. PubMed ID: 24156144
[No Abstract] [Full Text] [Related]
14. Pramlintide: FDA wants more.
Diabetes Obes Metab; 2001 Oct; 3(5):386. PubMed ID: 11710342
[No Abstract] [Full Text] [Related]
15. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
16. Amylin. Insulin's super sidekick.
Scheiner G
Diabetes Self Manag; 2010; 27(3):34, 37-8. PubMed ID: 20575326
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.
Kellmeyer TA; Kesty NC; Wang Y; Frias JP; Fineman MS
J Clin Pharmacol; 2007 Jul; 47(7):798-805. PubMed ID: 17463219
[TBL] [Abstract][Full Text] [Related]
18. Diabetes basics. Exenatide and pramlintide. New meds on the block.
Griffin S; Borders J
Diabetes Self Manag; 2006; 23(4):74-6, 79. PubMed ID: 16888865
[No Abstract] [Full Text] [Related]
19. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study.
Pencek R; Roddy T; Peters Y; De Young MB; Herrmann K; Meller L; Nguyen H; Chen S; Lutz K
Diabetes Obes Metab; 2010 Jun; 12(6):548-51. PubMed ID: 20518811
[TBL] [Abstract][Full Text] [Related]
20. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Leinung MC; Grasso P
Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
